447 related articles for article (PubMed ID: 25282560)
1. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.
Schmitt J; Spuls PI; Thomas KS; Simpson E; Furue M; Deckert S; Dohil M; Apfelbacher C; Singh JA; Chalmers J; Williams HC;
J Allergy Clin Immunol; 2014 Oct; 134(4):800-7. PubMed ID: 25282560
[TBL] [Abstract][Full Text] [Related]
2. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.
Schmitt J; Langan S; Deckert S; Svensson A; von Kobyletzki L; Thomas K; Spuls P;
J Allergy Clin Immunol; 2013 Dec; 132(6):1337-47. PubMed ID: 24035157
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review.
Gerbens LA; Prinsen CA; Chalmers JR; Drucker AM; von Kobyletzki LB; Limpens J; Nankervis H; Svensson Å; Terwee CB; Zhang J; Apfelbacher CJ; Spuls PI;
Allergy; 2017 Jan; 72(1):146-163. PubMed ID: 27322918
[TBL] [Abstract][Full Text] [Related]
4. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.
Spuls PI; Gerbens LAA; Simpson E; Apfelbacher CJ; Chalmers JR; Thomas KS; Prinsen CAC; von Kobyletzki LB; Singh JA; Williams HC; Schmitt J;
Br J Dermatol; 2017 Apr; 176(4):979-984. PubMed ID: 27858989
[TBL] [Abstract][Full Text] [Related]
5. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2021 Jul; 185(1):139-146. PubMed ID: 33393074
[TBL] [Abstract][Full Text] [Related]
6. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting.
Schmitt J; Spuls P; Boers M; Thomas K; Chalmers J; Roekevisch E; Schram M; Allsopp R; Aoki V; Apfelbacher C; Bruijnzeel-Koomen C; Bruin-Weller M; Charman C; Cohen A; Dohil M; Flohr C; Furue M; Gieler U; Hooft L; Humphreys R; Ishii HA; Katayama I; Kouwenhoven W; Langan S; Lewis-Jones S; Merhand S; Murota H; Murrell DF; Nankervis H; Ohya Y; Oranje A; Otsuka H; Paul C; Rosenbluth Y; Saeki H; Schuttelaar ML; Stalder JF; Svensson A; Takaoka R; Wahlgren CF; Weidinger S; Wollenberg A; Williams H
Allergy; 2012 Sep; 67(9):1111-7. PubMed ID: 22844983
[TBL] [Abstract][Full Text] [Related]
7. Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting report.
Jacobson ME; Thomas KS; Apfelbacher CJ; Leshem YA; Williams HC; Gerbens LAA; Spuls PI; Schmitt J; Howells L; Katoh N; Simpson EL;
Arch Dermatol Res; 2023 Nov; 315(9):2617-2622. PubMed ID: 37432466
[TBL] [Abstract][Full Text] [Related]
8. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
Chalmers JR; Simpson E; Apfelbacher CJ; Thomas KS; von Kobyletzki L; Schmitt J; Singh JA; Svensson Å; Williams HC; Abuabara K; Aoki V; Ardeleanu M; Awici-Rasmussen M; Barbarot S; Berents TL; Block J; Bragg A; Burton T; Bjerring Clemmensen KK; Creswell-Melville A; Dinesen M; Drucker A; Eckert L; Flohr C; Garg M; Gerbens LA; Graff AL; Hanifin J; Heinl D; Humphreys R; Ishii HA; Kataoka Y; Leshem YA; Marquort B; Massuel MA; Merhand S; Mizutani H; Murota H; Murrell DF; Nakahara T; Nasr I; Nograles K; Ohya Y; Osterloh I; Pander J; Prinsen C; Purkins L; Ridd M; Sach T; Schuttelaar ML; Shindo S; Smirnova J; Sulzer A; Synnøve Gjerde E; Takaoka R; Vestby Talmo H; Tauber M; Torchet F; Volke A; Wahlgren CF; Weidinger S; Weisshaar E; Wollenberg A; Yamaga K; Zhao CY; Spuls PI
Br J Dermatol; 2016 Jul; 175(1):69-79. PubMed ID: 27436240
[TBL] [Abstract][Full Text] [Related]
9. Reaching clinically relevant outcome measures for new pharmacotherapy and immunotherapy of atopic eczema.
Chalmers J; Deckert S; Schmitt J;
Curr Opin Allergy Clin Immunol; 2015 Jun; 15(3):227-33. PubMed ID: 26153875
[TBL] [Abstract][Full Text] [Related]
10. What are the best outcome measurements for atopic eczema? A systematic review.
Schmitt J; Langan S; Williams HC;
J Allergy Clin Immunol; 2007 Dec; 120(6):1389-98. PubMed ID: 17910890
[TBL] [Abstract][Full Text] [Related]
11. Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.
Leshem YA; Chalmers JR; Apfelbacher C; Katoh N; Gerbens LAA; Schmitt J; Spuls PI; Thomas KS; Howells L; Williams HC; Simpson EL;
JAMA Dermatol; 2022 Dec; 158(12):1429-1435. PubMed ID: 36223090
[TBL] [Abstract][Full Text] [Related]
12. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries.
Vermeulen FM; Gerbens LAA; Bosma AL; Apfelbacher CJ; Irvine AD; Arents BWM; Barbarot S; Deleuran M; Eichenfield LF; Manca A; Schmitt J; Vestergaard C; Wall D; Weidinger S; Middelkamp-Hup MA; Spuls PI; Flohr C;
Br J Dermatol; 2019 Sep; 181(3):492-504. PubMed ID: 30719709
[TBL] [Abstract][Full Text] [Related]
13. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2020 Nov; ():. PubMed ID: 33179283
[TBL] [Abstract][Full Text] [Related]
14. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative.
Leshem YA; Chalmers JR; Apfelbacher C; Furue M; Gerbens LAA; Prinsen CAC; Schmitt J; Spuls PI; Thomas KS; Williams HC; Simpson EL;
J Am Acad Dermatol; 2020 May; 82(5):1181-1186. PubMed ID: 31926221
[TBL] [Abstract][Full Text] [Related]
15. Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement.
Jacobson ME; Leshem YA; Apfelbacher C; Spuls PI; Gerbens LAA; Thomas KS; Williams HC; Katoh N; Howells L; Schmitt J; Deckert S; Seshadri R; Simpson EL;
JAMA Dermatol; 2024 May; ():. PubMed ID: 38776110
[TBL] [Abstract][Full Text] [Related]
16. Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review.
Gerbens LA; Chalmers JR; Rogers NK; Nankervis H; Spuls PI;
Br J Dermatol; 2016 Oct; 175(4):678-86. PubMed ID: 27012805
[TBL] [Abstract][Full Text] [Related]
17. The HOME Core outcome set for clinical trials of atopic dermatitis.
Williams HC; Schmitt J; Thomas KS; Spuls PI; Simpson EL; Apfelbacher CJ; Chalmers JR; Furue M; Katoh N; Gerbens LAA; Leshem YA; Howells L; Singh JA; Boers M;
J Allergy Clin Immunol; 2022 Jun; 149(6):1899-1911. PubMed ID: 35351441
[TBL] [Abstract][Full Text] [Related]
18. What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 3: nomenclature and outcome assessment.
Lloyd-Lavery A; Solman L; Grindlay DJC; Rogers NK; Thomas KS; Harman KE
Clin Exp Dermatol; 2019 Jun; 44(4):376-380. PubMed ID: 30706507
[TBL] [Abstract][Full Text] [Related]
19. Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial.
Thomas KS; Bradshaw LE; Sach TH; Cowdell F; Batchelor JM; Lawton S; Harrison EF; Haines RH; Ahmed A; Dean T; Burrows NP; Pollock I; Buckley HK; Williams HC; Llewellyn J; Crang C; Grundy JD; Guiness J; Gribbin A; Wake EV; Mitchell EJ; Brown SJ; Montgomery AA
Health Technol Assess; 2017 Apr; 21(16):1-260. PubMed ID: 28409557
[TBL] [Abstract][Full Text] [Related]
20. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries.
Gerbens LA; Boyce AE; Wall D; Barbarot S; de Booij RJ; Deleuran M; Middelkamp-Hup MA; Roberts A; Vestergaard C; Weidinger S; Apfelbacher CJ; Irvine AD; Schmitt J; Williamson PR; Spuls PI; Flohr C
Trials; 2017 Feb; 18(1):87. PubMed ID: 28241851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
